See All Slides - tctmd.com

Slides

Presentation TCT 2013

REPRISE II: A Prospective Registry Study of Transcatheter Aortic Valve Replacement with a Repositionable Transcatheter Heart Valve in Patients with Severe Aortic Stenosis

Presenter: Ian Meredith

October 31, 2013

Presentation TCT 2013

GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction

Presenter: Bernard Chevalier

October 31, 2013

Presentation TCT 2013

Pulmonary Embolism: When to Use Lytics, When to Use Novel Oral Anticoagulants

Presenter: Ori Ben-Yehuda

October 31, 2013

Presentation TCT 2013

Introduction and AHA Policy Statement

Presenter: H. Robert Superko

October 31, 2013

Presentation TCT 2013

Any Dedicated Valve Therapist with Hands-on TAVR Experience Can Provide Accurate Risk Assessment!

Presenter: Augusto Pichard

October 31, 2013

Presentation TCT 2013

Interventional Management of Cardiogenic Stroke

Presenter: Robert Sommer

October 31, 2013

Presentation TCT 2013

Outcomes of Patients Treated with Triple Antithrombotic Therapy After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (From the Harmonizing...

Presenter: Eugenia Nikolsky

October 31, 2013

Presentation TCT 2013

LEVANT 2

Presenter: D. Christopher Metzger

October 31, 2013

Presentation TCT 2013

Case #5: STEMI Complicated by Reperfusion Injury

Presenter: Thomas Engstr?m

October 31, 2013

Presentation TCT 2013

Genetic Testing for 9p21 can Cost Effectively Reduce Cardiovascular Events

Presenter: James Devlin

October 31, 2013

Advertisement

Slides

REPRISE II: A Prospective Registry Study of Transcatheter Aortic Valve Replacement with a Repositionable Transcatheter Heart Valve in Patients with Severe Aortic Stenosis

GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction

Pulmonary Embolism: When to Use Lytics, When to Use Novel Oral Anticoagulants

Introduction and AHA Policy Statement

Any Dedicated Valve Therapist with Hands-on TAVR Experience Can Provide Accurate Risk Assessment!

Interventional Management of Cardiogenic Stroke

Outcomes of Patients Treated with Triple Antithrombotic Therapy After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (From the Harmonizing...

LEVANT 2

Case #5: STEMI Complicated by Reperfusion Injury

Genetic Testing for 9p21 can Cost Effectively Reduce Cardiovascular Events

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content